Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.82% | -52.32% | -0.01% | -0.16% | 2.80% |
| Total Depreciation and Amortization | 91.95% | 106.82% | 79.75% | 54.13% | 30.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.44% | 21.29% | 24.23% | 26.87% | 23.38% |
| Change in Net Operating Assets | -639.06% | -993.74% | 62.45% | 106.93% | 123.01% |
| Cash from Operations | -137.75% | -89.16% | 17.11% | 30.65% | 37.20% |
| Capital Expenditure | 84.41% | 62.77% | -1.29% | -93.91% | -495.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 89.32% | -324.38% | -555.22% | -1,872.39% | -793.01% |
| Cash from Investing | 88.46% | -388.86% | -736.60% | -781.24% | -1,219.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3,907.69% | -1,973.68% | 72.59% | 95.47% | 96.73% |
| Issuance of Common Stock | -20.05% | 14,866.96% | 10,927.33% | 128.56% | 129.97% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -28.43% | 14,424.12% | 14,338.85% | 130.38% | 131.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -108.28% | -75.10% | 139.58% | 161.46% | 161.53% |